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We describe a cell-based kinetic profiling approach
using impedance readout for monitoring the effect of
small molecule compounds. This noninvasive readout
allows continuous sampling of cellular responses to
biologically active compounds and the ensuing kinetic
profile provides information regarding the temporal
interaction of compounds with cells. The utility of this
approachwas tested by screening a library containing
FDA approved drugs, experimental compounds, and
nature compounds. Compounds with similar activity
produced similar impedance-based time-dependent
cell response profiles (TCRPs). The compounds were
clustered based on TCRP similarity. We identified
novelmechanisms for existingdrugs,confirmedprevi-
ously reported calcium modulating activity for COX-2
inhibitor celecoxib, and identified an additional mech-
anism for the experimental compound monastrol. We
also identified and characterized a new antimitotic
agent. Our findings indicate that the TCRP approach
provides predictive mechanistic information for small
molecule compounds.
INTRODUCTION
Drug discovery and development is both a time- and resource-
intensive endeavor that is not always guaranteed to result in
safe and efficacious drugs. This problem was recently high-
lighted by issuance of a safety alert by the FDA for the diabetes
drug Avandia and also the withdrawal of the pain medication
Vioxx from the market (Nathan, 2007; Slordal and Spigset,
2006; Topol, 2004). At least part of the explanation centers on
the fact that modern drug discovery has mostly undertaken
a target-centric approach while the ultimate effect of drugs are
the culmination of on-target and less well understood off-target
interactions (Abraham, 2006). The potential interaction of drugs
with unintended targets or pathways could either prove fatal,
leading to toxicity and unwanted side effects, or could prove to
be beneficial. It is imperative to come up with strategies to iden-
tify and understand the specific biochemical nature of the on-
target activity as well as off-target activity of lead compounds712 Chemistry & Biology 16, 712–723, July 31, 2009 ª2009 Elsevierearlier in the drug discovery process in order to optimize struc-
tural features leading to desirable outcomes, while avoiding or
minimizing less desirable attributes. To address this issue
a number of multidimensional high throughput phenotypic
approaches have been proposed to assess the global responses
to specific perturbations in cells.
Multidimensional phenotypic profiling approaches including
gene expression profiling, proteomic profiling, protein-fragment
complementation profiling, high content microscopy-based
profiling, and cell line cytotoxicity-based profiling have the
capacity to measure both the interaction of compounds on
intended targets and also to generate testable hypotheses con-
cerning mechanism of action and off-target effects (Gunther
et al., 2003; Hieronymus et al., 2006; Leung et al., 2003; Mac-
Donald et al., 2006; Marton et al., 1998; Perlman et al., 2004;
Scherf et al., 2000;Wei et al., 2006;Weinstein et al., 1997; Young
et al., 2008). In all cases a very large information-rich data set is
generated that can be used to cluster compounds based on
profiles and search for specific patterns of activity. All the
profiling approaches have had various degrees of success not
only in elucidatingmechanism of action of unknown compounds,
but also unraveling new and novel targets for existing drugs.
The extent to which protein targets are modulated by drugs or
small molecule compounds is dependent on a number of factors,
including expression levels of the target, the effective concentra-
tion of the compound, and, importantly, the time needed for the
compound to perturb the target. Some compounds can be fast
acting, such as agonists of certain G protein-coupled receptors
or ion channels, leading to immediate biochemical and cellular
changes, while others can have a more prolonged effect. One
of the limitations of current multidimensional phenotypic profiling
approaches is that typically a single time point after compound
addition is chosen to assess the effect of the compound and
therefore the conclusion regardingmechanism of action is based
on the time point at which the samples are processed. It can be
envisioned that if the effect of the compound ismanifested at any
other time, or if a compound has multiple and kinetically distinct
effects, it can be easily overlooked. To address this limitation, we
have devised a live cell morphological profiling approach for
dynamic monitoring of the effect of small molecule compounds
that is based on impedance measurement of cells growing on
microelectronic sensors integrated in wells of microtiter plates
(Atienza et al., 2006). Microelectronic-based monitoring of cells
using impedance was first described by Giaever and KeeseLtd All rights reserved
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sive readout and cellular responses to treatments can be contin-
ually sampled inside the well throughout the length of the assay
(Giaever and Keese, 1993). The ensuing kinetic profile can
provide information regarding the temporal interaction of the
compounds with the cells. In this paper, we tested the utility of
impedance-based profiling approach by screening and profiling
a small compound library containing 2000 compounds of FDA
approved drugs, experimental biological compounds, and
nature compounds (Kocisko et al., 2003). We found that small
molecule compounds with similar biological activity produced
similar impedance-based time-dependent cell response profiles
(TCRPs). Due to the kinetic nature of the profiling approach both
short-term and long-term compound activity can be measured,
allowing for detection of temporally isolated but distinct activities
of small molecules and potentially off-target effects. These find-
ings indicate that using impedance-based monitoring and
profiling of cellular response upon exposure to biologically active
compounds can provide incisive and quantitative information
and novel mechanisms for existing drugs aswell as experimental
biological compounds and can be used to complement other
profiling approaches.
RESULTS
We have designed a real-time cell electronic sensing (RT-CES;
now known as xCELLigence RT-CA) system (Figure 1A) that
usesmicroelectronicplates (E-Plates) integratedwithgoldmicro-
electrode arrays on glass substrate in the bottom of the wells to
measure cellular status in real time (Solly et al., 2004). In the pres-
ence of media, application of low AC voltage (10 mV) produces
a small electric field between the electrodes that can be impeded
by the presence of adherent mammalian cells leading to large
changes in measured impedance (Figure 1A). The extent of
impedance change is proportional to the number of cells inside
the well and the inherent morphological and adhesive character-
istics of the cells. Figure 1B shows the time- and density-depen-
dent growth and proliferation of four different cell lines in the
E-Plates. Each cell line produces its own distinct growth kinetic
profiles due to unique morphological, adhesive, and growth
rate characteristics. Since it is well established that cellular prop-
erties at the level of cell number,morphology, and adhesive inter-
actions can be differentially modulated by biologically active
compounds (Abraham et al., 2008; Wang et al., 2008; Young
et al., 2008) we sought to determine how modulation of these
parameters by small molecule compounds affect the impedance
readout. Figure 1C shows the time-dependent effect of two cyto-
toxic compounds, the general kinase inhibitor staurosporine and
the anti-metabolite 5-fluorouracil (5-FU), on A549 cells. Even
though both of these compounds are well known apoptotic
inducers, they produced unique dose-dependent cell response
profiles and TCRPs. Interestingly, staurosporine appears to
have an immediate effect on the cells, while 5-FU takes a longer
time to manifest its effect. It was of interest to determine if the
TCRP can be predictive of biological mechanism; for example,
do compounds with similar mechanism produce similar TCRP?
To test the hypothesis that TCRP can be predictive of mecha-
nism of compound action, a 2000 compound library consisting of
FDA approved drugs (50%), natural products (29%), bioactiveChemistry & Biology 1compounds (18%), and herbicides and insecticides (3%) were
screened against A549 non-small lung cancer cells and PC3
prostate cancer cell lines using the RT-CES platform. While
TCRPs can be generated from both cell types, for the purposes
of this paper we will primarily show the data from A549 cells
and only discuss the data from PC3 cell lines for comparative
purposes. We measured both short and long-term compound
effects. For short term, the compound effect was monitored
every 2 min after compound addition for a total duration of 1 hr.
The high sampling frequency ensures the acquisition of imme-
diate and transient compound effects on the cell. The short-
term monitoring is automatically proceeded by long-term moni-
toring protocol collecting the data every 30 min from 1 hr to
48 hr after compound addition. This time duration was chosen
for the long-term response because it would allow sufficient
time for the compounds to interact and modulate their target(s)
and also result in sufficiently distinguishable TCRPs. Two
complementary approaches were undertaken to select the hits
from the screen. First, compounds were divided between those
resulting in short-term and long-term response. For short-term
response, any compound resulting in normalized cell index
change equivalent to 25% or greater of the mean of the control
(DMSO) at any time point between compound addition and 1 hr
later were chosen as a ‘‘hit.’’ For long-term responses, the crite-
rion for hit selectionwas a change in normalized cell index of 40%
or greater of control at any time point between 1 hr after
compound addition until the end of the screen. However, if a
compound resulted in normalized cell index values higher than
control for the entire duration of the long-term response, then
the hit selection criteria was set at 25% of control. The above
hit selection criteria of 25% or 40% over control for short-term
and long-term hits are chosen based on the consideration that
a false positive hit rate should be controlled at about 10%, taking
into account the assay variation in the RT-CES platform. These
criteria not only allow for the identification of compounds with
biological activity but also sufficiently distinguishable TCRPs to
be used for clustering analysis. The 1 hr selection for short-term
response is mainly based on consideration for identifying fast re-
sponding cellular events and is used as a demonstration of the
concept of separating time series data into different segments
for analysis. For other cells or other data from the RT-CES plat-
form, it may be possible to use different time windows for classi-
fying the cell response types. Based on the hit selection criteria
described we identified a total of 190 short-term and 261 long-
term hits using A549 cells. Performing the screen in PC3 cells
and applying the same criteria for hit selection resulted in a total
160 short-term and 440 long-term hits, with 75 common hits
between A549 in the early response and 104 common hits with
A549 cells in the late response. These results indicate that by ex-
panding the cell type for screening and profiling, it may be
possible to cover a larger subset of intracellular targets.
The hits from short-term response was treated as one group
and the hits from long-term response was subjected to an
agglomerative hierarchical clustering analysis as described in
the Experimental Procedures (Figure 2A). A complete list of the
clustered compounds is shown in Figure S2 (available online).
If TCRPs are indicative of biological activity then compounds
with similar biological activity would be grouped together.
Indeed, we could identify at least five clusters and subclusters6, 712–723, July 31, 2009 ª2009 Elsevier Ltd All rights reserved 713
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that can be associated with different mechanistic classes such
as calcium level and pathway modulators, steroidal nuclear
receptor modulators, antimitotics, DNA damaging agents, and
protein synthesis inhibitors (Figure 2A; Figures S1–S5).
The hits that were selected for their short-term response were
treated as one group and displayed two related impedance-
Figure 1. Real-TimeMonitoring of Adherent
Cells by the RT-CES System
(A) The RT-CES system is composed of a plate
station accommodating up to six 96 well E-Plates,
an electronic analyzer, and a computer that runs
the software for automatic and real-time data
acquisition and display. The E-Plates are inte-
grated with interdigitated gold microelectrodes.
A schematic representation of microelectrodes
and the principle of using cell electrode imped-
ance to noninvasively measure adherent cells are
shown. In the absence of cells, the baseline
impedance (Z0) at time zero (t0) represents the
impedance of the gold microelectrodes. Addition
of cells to the sensor microelectrodes leads to
changes in impedance signal at time t1 (Zcellt1)
that is directly proportional to the number of cells
seeded on the sensors and is displayed as the
cell index. The cell index value changes with time
(Zcellt2) and reflects the morphology, adhesion,
and number of cells inside the well.
(B) Real-time monitoring of the density-dependent
growth and proliferation of four cell lines on the
RT-CES platform. The cells suspensions were
transferred to E-Plates and placed on the RT-
CES reader for real-time monitoring every 30 min
for the duration of the assay.
(C) TCRPs of two different cytotoxic agents using
A549 cells. The arrow indicates the point of
compound addition.
based TCRPs (Figure 2B). In both
instances there was an immediate drop
in cell index (within 5 min) followed by
either partial or complete recovery of
the cell index curve similar to control
curve or, alternatively, the other group
continued to maintain very low cell
indices after the initial decline most likely
due to cytotoxicity. Analysis of the
compounds with known mechanisms in
these groups revealed that the majority
of these compounds are antagonists of
various G protein-coupled receptor
signaling pathways including that of
histamine, dopamine, and serotonin
receptors (Figure 2B; Figure S2). Interest-
ingly, most of these compounds dis-
played similar TCRP in PC3 cells as well
(data not shown), indicating their mode
of action and consequent morphological
cellular response is similar in both cell
lines. Based on structural considerations,
the hits with known mechanisms in this
category can be divided into several structurally related groups
of compounds, including thioxanthenes, phenothiazines, diben-
zazepines, dibenzoxazepines, selective estrogen receptor
modulators, dihydropyridine, and estrogenic compounds
(Figure 2B). Closer examination of compounds in this category
revealed another common underlying mechanistic feature,
which is modulation of intracellular calcium levels or pathways714 Chemistry & Biology 16, 712–723, July 31, 2009 ª2009 Elsevier Ltd All rights reserved
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Impedance-Based Cell Response Profilingwithin the cells either directly or indirectly. For example, the
compound amlodipine besylate is a well know L-type voltage-
gated calcium channel inhibitor, while triflupromazine and other
phenothiazines are known to interfere with the pleiotrophic effect
of calcium/calmodulin action on intracellular pathways (Epstein
et al., 2007; Motohashi, 1991). Interestingly, selective estrogen
receptor modulators such as tamoxifen, a well known estrogen
receptor antagonist, also resulted as a hit in this category.
Indeed, tamoxifen can cause an increase in intracellular calcium
concentrations in a number of cell types (Greenberg et al., 1987;
Zhang et al., 2000). Furthermore, there is also evidence that
tamoxifen can directly bind and inhibit calmodulin (Lam, 1984).
A number of nuclear hormone receptor agonists, including
those that modulate glucocorticoid receptor, mineralcorticoid
receptor, progesterone receptor, and androgen receptor, clus-
tered together (Figure 2C and Figure S3). The unique TCRP for
this category is characterized by an increase in cell index above
the control curve throughout the length of the assay. We have
also observed similar TCRP for agonists of peroxisome prolifer-
ator activated receptor and retinoic acid receptor (data not
shown). The fact that modulators of all of these nuclear hormone
receptors display similar TCRPs suggests that in addition to their
specific effects they share common mechanisms leading to
similar cellular effects. One of the common features of nuclear
hormone receptors is that they can induce G1 arrest in certain
cell types (Wu et al., 2006), possibly through upregulation of
cyclin-dependent kinase inhibitors (Addeo et al., 2004). Interest-
ingly, using a high content microscopy profiling approach,
Young et al. (2008) also observed that most corticosteroid
compounds clustered as a group that they identified as G1 arrest
phenotype. However, the nuclear receptor-like responses using
impedance measurement appears to be cell type specific as we
did not observe similar response profiles for these groups of
compounds in PC3 cells (data not shown).
Another group of compounds whose TCRP coclustered are
well characterized modulators of tubulin polymerization
(Figure 2D; Figure S4). The impedance-based TCRP for these
compounds are characterized by an initial steady decline in
cell index followed by recovery after about 14–16 hr after treat-
ment. This category includes compounds such as paclitaxel,
colchicine, nocadazole and nocadazole-related compounds,
and podophyllotoxins. Our screening assay does not seem to
distinguish between agents stabilizing microtubules such as
paclitaxel and agents that disrupt or prevent tubulin polymeriza-
tion such as nocadazole (Jordan and Wilson, 2004). It is likely
that the TCRP we observe here is reflective of a common under-
lying global cellular response to these classes of compounds
such as cell cycle arrest at mitosis, characterized by unique
morphological features such as cell rounding and transientChemistry & Biology 16detachment of the cells (Jordan and Wilson, 2004). To better
understand this pattern, we treated cancer cells with paclitaxel
and fixed and stained the cells with antitubulin antibodies at
different time points after treatment (Figure S6). The initial
decline in cell index correlates with morphological changes
due to cell rounding as a result of mitotic arrest. At 16 hr, which
is coincident with the lowest point of cell index in the TCRP, the
majority of the cells (85%–90%) are arrested at mitosis deter-
mined by intense staining of the spindle apparatus by antitubulin
antibody. The recovery of the cell index 24 hr after treatment
correlates with a subpopulation of cells escaping the arrest
and are larger cells that have failed to undergo cytokinesis.
This phenomenon has been described as mitotic slippage and
is observed in cell types lacking a robust mitotic checkpoint
(Weaver and Cleveland, 2005). In addition, nontubulin-targeting
compounds, such as monastrol, which inhibits the mitotic kine-
sin Eg5, also display similar TCRP as those of tubulin-targeting
agents in our assays (see Figure 4). Collectively, the data demon-
strate the impedance-based TCRPs are a reflection of global
cellular morphological responses to antimitotic agents and
represent a unique signature for mitotic arrest. Exposure of a
panel of six other cell types to paclitaxel and other tubulin-
targeting agents resulted in overall similar TCRPs (Figure S6B).
Another major subcluster in our analysis is composed of
compounds interfering with DNA synthesis, unwinding and repli-
cation, and transcription and translation. The TCRP for these
compounds is characterized by an initial and sustained increase
in cell index above that of the control followed by a decrease in
cell index below control levels, reflecting an ultimate cytotoxic
response (Figure 2E). These compounds primarily include topoi-
somerase inhibitors and antimetabolites (Figure 2E; Figure S5).
Within this cluster, we also observed a subcluster containing
TCRPs for compounds inhibiting protein translation such as cy-
clohehimide and emetine (Figure 2F). The compounds in this
category are also known to induce cell-cycle arrest primarily at
G1, S, or G1/S transition followed by induction of cell death.
The data thus far support the hypothesis that TCRP can be
used to cluster compounds with similar mechanism of action.
However, the utility of such an approach is best determined by
the predictive value it may provide as a compound screening
or profiling tool. We next analyzed the TCRP within each cluster
to determine its predictive capacity for compounds with
unknown mechanism or other reported mechanisms.
We analyzed the compounds in the calcium level and pathway
modulators group and noticed that the TCRP for celecoxib, a
cyclooxygenase-2 (COX-2) inhibitor, was present in this group.
COX-2 inhibitors, such as rofecoxib, valdecoxib, deracoxib, and
celecoxib, have received considerable attention recently due to
cardiotoxicity side effects and all these compoundswere presentFigure 2. Clustering Analysis and TCRPs of Compounds Associated with Different Mechanistic Groups
(A) Agglomerative, hierarchical clustering analysis of TCRPs in the long-term response. The descriptor is the change in cell index as a function of time. A complete
list of the compounds is shown in Figure S2.
(B) Typical A549 TCRPs of short-term response group together with compound classes.Most compounds in this subgroup appear to be antagonists of G protein-
coupled receptors and modulators of calcium. The light blue arrow on the x axis in this graph and proceeding graphs indicates that the short-term data was
collected every 2 min.
(C) Typical A549 TCRP associated with compounds and compound classes that modulate the nuclear hormone receptors.
(D) Typical A549 TCRP for tubulin-modulating compounds and compound classes.
(E) Typical A549 TCRP for compounds that affect nucleotide and DNA synthesis.
(F) Typical A549 TCRP for compounds that affect protein synthesis., 712–723, July 31, 2009 ª2009 Elsevier Ltd All rights reserved 717
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Impedance-Based Cell Response Profilingin the library (Figure 3A). Interestingly, at the concentrations at
which the screen was conducted only celecoxib resulted as
a hit among the four structurally related compounds. Based on
the immediate TCRP for celecoxib, the prediction is that cele-
coxib may be modulating calcium levels within the cell. Indeed,
it has been shown previously that celecoxib treatment leads to
an immediate increase in internal calcium levels within the cell
(Pyrko et al., 2007; Tanaka et al., 2005). To confirm this observa-
tion, we measured calcium levels in A549 cells after treating with
different doses of celecoxib and thapsigargin as positive control.
Celecoxib treatment led to a dose-dependent increase in
calcium, as shown previously (Figure 3B).Testing rofecoxib at
the same doses did not lead to any detectable calcium release
(data not shown). These results support theargument that in addi-
tion to inhibiting COX-2, celecoxib may function by alternative
mechanisms, especially at doses ultimately resulting in cytotox-
icity (Kardosh et al., 2008; Pyrko et al., 2007). From a structure
activity relationship, it is interesting that all the COX-2 inhibitors
shown in Figure 3A share a common backbone structure, yet
the unique side group modifications of celecoxib afford it the
ability to modulate intracellular calcium levels. This observation
also underscores the challenge in target-driven drug discovery
where it is easy to introduce and overlook activities unrelated to
the target during the lead optimization process.
In the nuclear hormone modulator cluster we identified the
compound rifampin, an antibiotic used for the treatment of tuber-
culosis (Zhang and Amzel, 2002)(Figure 3C; Figure S2). Rifampin
acts directly on messenger RNA synthesis in prokaryotes by
inhibiting DNA-primed RNA polymerases, especially those of
gram-positive bacteria such as Mycobacterium tuberculosis.
Rifampin has been shown to act as an agonist for glucocorticoid
receptors (Calleja et al., 1998).
Close examination of the compounds resulting inmitotic arrest
TCRP revealed that there are other compounds and drugs not
readily recognized for their antimitotic activity (Figure S4). One
of these is estradiol, estrogen receptor agonist (Figure 3D). It
has been shown that estradiol and some of its analogs disrupt
microtubule polymerization by directly binding to tubulin (Aizu-
Yokota et al., 1994; Bogatcheva et al., 2007; Tinley et al.,
2003). As a matter of fact, one of the breakdown products
of estradiol with antiproliferative and tubulin binding properties,
2-methoxyestradiol, is currently in clinical trials for metastatic
breast cancer (James et al., 2007).
In a separate screen in A549 cells we also identified the
compound dibenzyltrisulfide (DBTS), a bioactive natural
compound found in a subtropical shrub, Petiveria alliacea (Ros-
ner et al., 2001), displaying similar TCRP as that of epothilone B
(Figure S6C). Based on the TCRP pattern, we hypothesized
DBTS may induce mitotic arrest by targeting tubulin polymeriza-
tion. Indeed, treatment of MCF-7 cells with DBTS disrupts the
microtubule cytoskeleton compared to cells treated with DMSO
(Figure S6D). To determine if DBTS directly target tubulin poly-
merization, microtubule assembly assay was performed in the
presence of increasing concentrations of DBTS (Figure S6E).
DBTS dose dependently inhibited tubulin assembly into microtu-
bules, suggesting that it induces mitotic arrest by directly target-
ing tubulin polymerization.
In the DNA-damaging subcluster a group of compounds
known as cardiac glycosides were identified. These compounds718 Chemistry & Biology 16, 712–723, July 31, 2009 ª2009 Elsevierare members of the digoxin family widely used for treatment of
heart conditions (De Mey and Snoeck, 1980). They act by inhib-
iting the sodium/potassium (Na/K) ATPase pump in heart cells,
slowing down the extrusion of calcium and causing increased
contractility. In our screen, digoxin and related compounds co-
clustered with compounds inducing DNA damage such as topoi-
somerase inhibitors (Figure 3F). These results are corroborated
by recent publications demonstrating certain cardiac glycosides
can inhibit topoisomerase I and II, providing an explanation for
the similarity in their TCRPwith DNAdamaging agents (Bielawski
et al., 2006; Lopez-Lazaro et al., 2005). Interestingly Young et al.
(2008), using high content microscopy also demonstrated
cardiac glycoside family coclustered with DNA damaging
agents.
One of the major obstacles in the target-centric approach to
drug discovery is lack of a methodology for identifying and
understanding potential off-target effects. We wanted to deter-
mine if the TCRP approach can be used to identify off-target
activity of compounds. Testing the compound monastrol in
A549 cells resulted in a biphasic, short- and long-term TCRPs
(Figure 4A). The long-term TCRP is similar to antimitotic agents
as expected based on the reportedmechanism of action ofmon-
astrol (Mayer et al., 1999) and was confirmed by phospho-
histone H3 staining (Figure 4A, right). The short-term response,
while unexpected, resembles the profile of compounds modu-
lating intracellular calcium levels (Figure 2B) and also leads to
a transient change in cell morphology as judged by staining of
the actin cytoskeleton (data not shown). The compound S-tri-
tyl-cysteine, another Eg5 inhibitor (DeBonis et al., 2004), also
led to mitotic arrest TCRP but did not induce the early phase
response (Figure 4A). This observation indicated the calcium
modulator-like response maybe an off-target effect or additional
mechanism of monastrol, rather than relating to inhibition of Eg5.
Searching the literature using the chemical name for the core
structure of monastrol, 6-methyl-2-thioxo-1,2,3,4-tetrahydro-
pyrimidine-5-carboxylate, yielded at least one reference indi-
cating compounds resembling monastrol contain calcium
channel antagonistic activity (Kumar et al., 2002). We sought to
test the possibility that monastrol treatment may modulate the
activity of voltage-gated L-type calcium channels. This was
tested by measuring calcium uptake through voltage-gated
L-type calcium channel Cav1.2 stably expressed in HEK293
cells. The data in Figure 4B shows that at concentrations at
which monastrol induces mitotic arrest TCRP (Figure 4A), it
significantly blocks calcium uptake (about 70% inhibition)
through Cav1.2 channels, while S-trityl-cysteine did not have
any significant effects. Nifedipine, a known inhibitor of voltage-
gated L-type channels, potently inhibited (94.7%) calcium
uptake in this assay. While we can’t rule out other mechanisms,
the data is consistent with the prediction that monastrol can
modulate L-type voltage-gated calcium channel activity in addi-
tion to targeting Eg5.
DISCUSSION
The approach described in this paper brings to bear two impor-
tant features of impedance-based monitoring of cellular
response upon compound treatment that are important for
generating mechanism-specific profiles. First, the interaction ofLtd All rights reserved
Chemistry & Biology
Impedance-Based Cell Response ProfilingFigure 3. TCRPs Can Be Predictive of Mechanism of Action
(A) COX-2 inhibitors valdecoxib, rofecoxib, deracoxib, and celecoxib were tested in A549 cells at different doses. Only celecoxib resulted in a short-term
response TCRP, indicating it might affect calcium levels inside the cell.
(B) Direct measurement of calcium levels in the cell using fura-2 demonstrated that celecoxib can induce an increase in calcium levels inside the cell.
(C) The TCRP for rifampin coclustered with well known modulators of nuclear hormone receptors, such as hydrocortisone.
(D) The TCRP for estradiol coclustered with those of other tubulin-modulating agents such as colchicine.
(E) Compounds with similar backbone structure to digoxin resulted in TCRP similar to camptothecin, indicating that they may affect DNA synthesis or repair as
predicted by the TCRP.Chemistry & Biology 16, 712–723, July 31, 2009 ª2009 Elsevier Ltd All rights reserved 719
Chemistry & Biology
Impedance-Based Cell Response Profilingadherent cells with the microelectrodes and generation of
impedance response is dependent on three cellular parameters,
namely, cell number, morphology, and attachment quality. All
three parameters are intricately linked to signaling pathways
regulating various facets of cellular physiology and therefore
amenable to modulation by biologically active small molecule
compounds in a manner that is dependent on mechanism and
concentration of the compound being tested. Rather than
measuring compound activity against a single target or pathway,
our approach allows for expansion of the biological space at
which a compound is screened and provide ample opportunity
to identify biological activity of small molecule compounds in
an unbiased manner. Because the impedance readout is nonin-
vasive, it allows for the other critical feature of our approach,
which is inclusion of time resolution in the screening assay.
Time-dependent compound interaction with cells and unique
modulation of cell number, adhesion, and overall morphology
ultimately cumulate in TCRP, which can be used to distinguish
between compounds with different activities. The time factor is
Figure 4. Using the Time Resolution Offered by
TCRP to Identify Off-Target Effect for Compounds
with Established Activity
(A) Monastrol and S-trityl-cysteine result in a long-term
TCRP indicative of mitotic arrest. Monastrol (100 mM final
concentration) but not S-trityl-cysteine (11 mM final
concentration) leads to a short-term response profile
indicative of modulation of calcium. The right panel shows
staining of A549 cells with phospho-histone H3 antibody
after treatment with monastrol for 16 hr.
(B) Treatment HEK293 cells stably expressing the human
Cav1.2 voltage-gated L-type calcium channel with mon-
astrol (100 mM) leads to inhibition of calcium uptake (*p <
0.001 compared to control), while S-trityl-L-cysteine (20
mM) does not have a significant effect. The error bars
represent standard deviations (n of at least four samples)
and the data is representative of at least three indepen-
dent experiments.
critical in assessing compound activity(s) as
the modulation of the target by the compound
or consequent manifestation of the cellular
response can be time dependent. Therefore,
the results obtained by other screening and
profiling approaches are dependent on the
time point at which the assay is processed
and any activity that may manifest itself
at a time other than the end point can be
missed.
We have demonstrated the importance of the
temporal resolution in the assay by using the
TCRP to predict a calcium-modulating activity
for celecoxib, a COX-2 inhibitor (Figures 3A
and 3B). Our observation is supported by recent
papers, indicating some aspects of celecoxib
activity may be COX-2 independent (Kardosh
et al., 2008; Pyrko et al., 2007). The time-depen-
dent dual activity of monastrol also highlights
the predictive aspect of our current approach.
The TCRP allowed us to identify a potential
calcium channel inhibitory activity of monastrol not described
previously (Figure 4).
While the data presented here support the hypothesis that
TCRP can be predictive of mechanism of action and potential
off-target drug interactions, we feel that the overall predictive
value of the system can be improved by performing the screen
and clustering, taking into account the dose response of the
compounds and by expanding the pool of cells. Similar to the
NCI 60 cell line panel, the TCRP of compounds across multiple
cell lines would allow greater coverage of the expanse of targets
being screened and can improve the predictive capacity of the
assay. Because the assay is not limited to cell lines or genetically
modified cells, primary or disease-relevant cell types can also be
used, making the predictive value of the assay more physiolog-
ically relevant. Finally, the TCRP approach can be an important
complement to previously described compound profiling
approaches such as high content microscopy. The time resolu-
tion of impedance-based TCRP can be combined with the multi-
plexing power of high content microscopy to focus in on specific720 Chemistry & Biology 16, 712–723, July 31, 2009 ª2009 Elsevier Ltd All rights reserved
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the on- or off-target drug interactions.
SIGNIFICANCE
The extent to which protein targets are modulated by drugs
or small molecule compounds is dependent on a number of
factors, including the expression levels of the target, the
effective concentration of the compound, and the time
needed for the compound to perturb the target. One of the
limitations of current multidimensional phenotypic profiling
approaches is that typically a single time point is chosen
to assess the effect of compounds and the conclusion
regarding the mechanism of action of the compound is
based on the time point at which the samples are processed.
It can be envisioned that if the effect of the compound is
manifested at any other time, or if a compound has multiple
and kinetically distinct activities, it can be overlooked. The
TCRP approach described in thiswork addresses this limita-
tion because the profile generated is time dependent and, in
combinationwithmeasurement of cell number,morphology,
and adhesion, allows greater expansion of the ‘‘biological
space’’ at which compounds are screened and provides
ample opportunity to detect and identify biological activity
associated with small molecules. The utility of the TCRP
approach was demonstrated by identifying activities and
‘‘off-target effects’’ for certain drugs currently in use in the
clinic and experimental compounds. The time resolution
provided by the TCRP approach can be used in conjunction
with phenotypic profiling approaches to obtain additional
mechanistic data associated with small molecule
compounds.
EXPERIMENTAL PROCEDURES
Cell Culture
All the cells used in this study were purchased from American Type Culture
Collection. Cells were cultured in a standard humidified incubator at 37C
with 5% CO2 according to optimal media and growth conditions specified
by American Type Culture Collection.
Reagents
All the reagents were purchased from Sigma unless indicated otherwise.
The Spectrum 2000 compound library was purchased from MS Discovery.
Phospho-histone H3 (Ser 10) antibody was purchased from Cell Signaling
Technologies.
Time-Dependent Cell Response Profiling Using the RT-CES
The RT-CES system has been described previously (Atienza et al., 2006; Solly
et al., 2004). For time-dependent cell response profiling, 90 ml of media was
added to 96 well E-Plates to obtain background readings followed by the addi-
tion of 100 ml of cell suspension. The E-Plates containing the cells were allowed
to incubate at room temperature for 30 min and placed on the reader in the
incubator for continuous recording of impedance as reflected by cell index.
After 20–24 hr the cells were treated with the compounds from the library.
To prepare the compounds for screening, 2 ml of compounds (10 mM) dis-
solved in DMSO were transferred from the compound plate to 96 well round
bottommicrotiter plates and diluted with 50 ml of cell growthmedia. Tenmicro-
liters of the diluted compounds were then transferred to the E-Plate containing
the cells (20 mM final) . Each compound dilution plate also contained DMSO-
only diluted wells as well as media-only wells in addition to wells containing
25 nM paclitaxel and 1 mM MG132. The cells were monitored every 2 min for
the duration of 1 hr after compound addition to capture the short-termChemistry & Biology 1response and for every 30 min from 1 hr after compound addition to about
48 hr to capture the long-term response.
Impedance and Cell Index Measurements by RT-CES System
To quantify cell status based on the measured cell-electrode impedance,
a parameter termed cell index (CI) is derived, according to the following equa-
tion:
CI= max
i =1;.;N

RcellðfiÞ
RbðfiÞ  1

;
where Rb(f) and Rcell(f) are the frequency-dependent electrode resistances
(a component of impedance) without cells or with cell present, respectively.
N is the number of the frequency points at which the impedance is measured.
Thus, cell index is a quantitative measure of the status of the cells in an elec-
trode-containing well. Under the same physiological conditions, more cells at-
taching onto the electrodes leads to larger Rcell(f) value, leading to a larger
value for cell index. Furthermore, for the same number of cells present in the
well, a change in the cell status such as morphology will lead to a change in
the cell index. A ‘‘normalized cell index’’ at a given time point is calculated
by dividing the cell index at the time point by the cell index at a reference
time point. Thus, the normalized cell index is 1 at the reference time point.
Fluorescence Microscopy
A549 cells were seeded in 16 well Lab-tec chamber slides and allowed to
attach and spread for 24 hr. The cells were treated with compounds at the indi-
cated final concentrations and fixed with 100% ice cold methanol. The cells
were permeabilized in PBS containing 0.2% Triton X-100, washed and
blocked with PBS containing 0.5% BSA, followed by staining with either
FITC-conjugated antitubulin antibody or anti-phospho-histone H3 antibody
(S-10). The cells were washed three times with PBS, treated with anti-fade
reagent containing DAPI (Invitrogen), and visualized and imaged using a Nikon
E400 epifluorescence microscope and Nikon ACT software.
Calcium Measurements
A549 cells and HEK293 cells stably expressing hCav1.2 a and b cDNAs
(Chantest) were seeded in 96 well clear bottom black wall plastic culture plates
and transferred to a recording chamber of Molecular Devices FLIPR imaging
system. Cellular fluorescence was excited by 488 nm illumination through
the bottom of 96 well plate by an argon laser and dye fluorescence imaged
with a cooled CCD camera. Fluorescence was displayed on line and saved
in a file for offline analysis with FLIPRControl software.
For calciummeasurements, the cells were loaded with 4 mMFluo-3AM ester
dye and 0.4% pleuronic acid in Hanks buffer-phosphate solution (HB-PS) for
1 hr at room temperature. For celecoxib-mediated calcium release, A549 cells
were washed twice in HB-PS assay buffer and the assay was performed in this
assay. For monastrol experiments in HEK293-Cav1.2 cells, cells were washed
twice with Ca-free HB-PS assay buffer and the assay was performed in this
buffer. Fluorescence from each plate wasmonitored for stability of signal. After
a uniform response was obtained from the plate in a mock experiment without
fluid addition, the measurement with fluid addition was started. The recording
consisted of a 30 s period of baseline data followed by addition of compound
plate solutions to each well. The effect of the compounds were monitored for
13.5 min, the first 2 min sampled at a frequency of one sample every second
and the last 12 min at a frequency of one sample every 5 s. Control data
were subtracted from the test article data to remove background changes
in the signal. For monastrol experiment, the compounds were prepared in
Na-free HB-PS to depolarize cells with a final concentration of 72 mM KCl
and an increased extracellular calcium from 0 to 5 mM at the time of fluid
addition.
Microtubule Assembly Assays
Microtubule assembly assays were performed using the fluorescence-based
Tubulin polymerization kit from Cytoskeleton, Inc. Briefly, 2 mg/mL tubulin
(Cytoskeleton) was mixed with DBTS at different final concentrations
(30 mM, 10 mM, 3 mM, 1 mM, and 0.5 mM), vincristine (1.5 mM), or DMSO, and
the polymerization reaction was performed at 37C in 20% glycerol, 80 mM
PIPES, 2.0 mM MgCl2, 0.5 mM EGTA (pH 6.9), and 1 mM GTP and monitored6, 712–723, July 31, 2009 ª2009 Elsevier Ltd All rights reserved 721
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excitation and emission of 360 nm and 450 nm, respectively.
Clustering Analysis
The TCRPs for the hits were subjected to an agglomerative, hierarchical clus-
tering analysis (http://en.wikipedia.org/wiki/Cluster_analysis) classified into
different clusters so that the TCRPs within a cluster shared the same or similar
patterns. The algorithm treats each response curve as a separate cluster and
merges them into successively larger clusters by continuously calculating
distances between TCRP curves, searching for minimum distances and
grouping minimum-distance curves into a cluster. The following approaches
were taken in the curve clustering algorithm: (1) TCRP curves were normalized
at the last measurement time point prior to compound addition; (2) the normal-
ized cell index curveswere projected to a common time coordinate using inter-
polation so that the TCRP curves from different experiments with different
impedance-measurement time points can be directly compared and the
distances between these curves can be calculated; (3) the Euclidean distance
in an n spacewas used as the distance between two single curves each having
n data points; (4) searching forminimumdistance between two curves by fixing
one curve and moving another one horizontally (time) within a small and given
region (4 min) to correct the effects of experimental variations in compound
addition time for different wells on the calculation of the distance between
different response profiles. In this work, the straight forward Euclidean
distance-based hierarchical clustering algorithm is used for demonstrating
the profiling of the cell responses based on a time-dependent series data. It
is recognized that one may use other approaches for defining the distances
between curves or other clustering methods for analyzing the TCRPs.
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